• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

作者信息

Salar Antonio, Domingo-Domenech Eva, Panizo Carlos, Nicolás Concepción, Bargay Joan, Muntañola Ana, Canales Miguel, Bello José Luis, Sancho Juan Manuel, Tomás José Francisco, Rodríguez María José, Peñalver Javier, Grande Carlos, Sánchez-Blanco José Javier, Palomera Luis, Arranz Reyes, Conde Eulogio, García Mar, García Juan Fernando, Caballero Dolores, Montalbán Carlos

机构信息

Department of Hematology, Hospital del Mar, Barcelona, Spain.

Department of Hematology, Hospital Durans i Reynals, Barcelona, Spain.

出版信息

Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11.

DOI:10.1182/blood-2017-07-795302
PMID:28801448
Abstract
摘要

相似文献

1
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.利妥昔单抗与苯达莫司汀治疗黏膜相关淋巴组织淋巴瘤2期研究的长期结果
Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11.
2
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.苯达莫司汀联合利妥昔单抗方案对原发性淋巴结边缘区B细胞淋巴瘤有效。
Hematol Oncol. 2017 Dec;35(4):536-541. doi: 10.1002/hon.2334. Epub 2016 Jul 22.
3
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.利妥昔单抗单药治疗或联合苯达莫司汀并不逊于利妥昔单抗-CHOP 方案治疗真实世界中脾边缘区淋巴瘤患者。
Acta Haematol. 2021;144(3):322-326. doi: 10.1159/000509596. Epub 2020 Sep 4.
4
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.苯达莫司汀联合利妥昔单抗成功治疗边缘区淋巴瘤相关抗磷脂抗体
BMJ Case Rep. 2019 Mar 14;12(3):e224636. doi: 10.1136/bcr-2018-224636.
5
Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.苯达莫司汀和利妥昔单抗作为结外黏膜相关边缘区淋巴瘤的一线治疗：单中心经验。
Oncol Res. 2024 May 23;32(6):1031-1036. doi: 10.32604/or.2024.046885. eCollection 2024.
6
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.苯达莫司汀和利妥昔单抗作为有症状脾边缘区淋巴瘤的一线治疗：BRISMA/IELSG36 II期研究的长期结果及早期不可测量的微小残留病达到情况的影响
Haematologica. 2024 Jul 1;109(7):2297-2302. doi: 10.3324/haematol.2023.284109.
7
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.苯达莫司汀和利妥昔单抗治疗边缘区淋巴瘤的疗效：来自 II 期 BRISMA/IELSG36 研究的结果。
Br J Haematol. 2018 Dec;183(5):755-765. doi: 10.1111/bjh.15641. Epub 2018 Nov 8.
8
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.苯达莫司汀-利妥昔单抗方案治疗未经治疗的惰性边缘区淋巴瘤：65 例患者的经验。
Hematol Oncol. 2020 Oct;38(4):487-492. doi: 10.1002/hon.2773. Epub 2020 Jul 29.
9
Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).利妥昔单抗-苯达莫司汀（R-Benda）用于治疗合并原发性干燥综合征（pSS）的黏膜相关淋巴组织淋巴瘤（MALT淋巴瘤）
Br J Haematol. 2019 Feb;184(3):472-475. doi: 10.1111/bjh.15120. Epub 2018 Feb 9.
10
CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.边缘区淋巴瘤中 CD5 的表达预示着对利妥昔单抗或苯达莫司汀/利妥昔单抗的反应存在差异。
Leuk Lymphoma. 2022 Jan;63(1):31-42. doi: 10.1080/10428194.2021.1973670. Epub 2021 Sep 1.

引用本文的文献

1
MALToma with a 'B'-Not for Benign, but for Bronchus-Associated: A Rare Case of Bronchus-Associated Lymphoid Tissue Lymphoma.伴有“B”的MALToma——并非良性，而是与支气管相关：一例罕见的支气管相关淋巴组织淋巴瘤病例
J Investig Med High Impact Case Rep. 2025 Jan-Dec;13:23247096251366125. doi: 10.1177/23247096251366125. Epub 2025 Aug 20.
2
SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma.SOHO最新技术进展与后续问题 | 边缘区淋巴瘤的当前及新出现的新型治疗方法
Clin Lymphoma Myeloma Leuk. 2025 May 31. doi: 10.1016/j.clml.2025.05.021.
3
Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.
边缘区淋巴瘤的发病机制、诊断、治疗及预后进展
Curr Treat Options Oncol. 2025 Feb;26(2):142-155. doi: 10.1007/s11864-025-01293-w. Epub 2025 Feb 1.
4
Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma.新诊断的边缘区淋巴瘤的特征、疗效和预后分析。
Front Immunol. 2024 Sep 23;15:1466859. doi: 10.3389/fimmu.2024.1466859. eCollection 2024.
5
Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma.一线单药利妥昔单抗治疗结外边缘区淋巴瘤的疗效与安全性
Eur J Haematol. 2025 Jan;114(1):70-78. doi: 10.1111/ejh.14306. Epub 2024 Sep 18.
6
Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea.韩国晚期边缘区淋巴瘤治疗的德尔菲共识建议。
Ann Hematol. 2024 Sep;103(9):3615-3625. doi: 10.1007/s00277-024-05907-5. Epub 2024 Aug 6.
7
Ophthalmic Manifestations in Patients with Blood Malignancies.血液系统恶性肿瘤患者的眼部表现
Hematol Rep. 2024 Mar 28;16(2):193-203. doi: 10.3390/hematolrep16020020.
8
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.边缘区淋巴瘤国际预后指数：一种适用于需要全身治疗的边缘区淋巴瘤的统一预后指数。
EClinicalMedicine. 2024 Apr 11;72:102592. doi: 10.1016/j.eclinm.2024.102592. eCollection 2024 Jun.
9
B-cell non-Hodgkin lymphomas.B 细胞非霍奇金淋巴瘤。
Lancet. 2024 May 4;403(10438):1791-1807. doi: 10.1016/S0140-6736(23)02705-8. Epub 2024 Apr 10.
10
More is not always better, sometimes it is just more.更多并不总是更好，有时只是数量更多而已。
Haematologica. 2024 Aug 1;109(8):2395-2397. doi: 10.3324/haematol.2024.285019.